Supply of Naloxone Nasal Spray

This tender for Naloxone Nasal Spray demonstrates good basic information and a clear e-procurement process, but significant concerns exist regarding the lack of full tender documentation access without an NDA, missing evaluation criteria, and vague technical requirements.

The tender defines the procedure and references national law, but the missing mandatory exclusion grounds and the requirement for an NDA prior to document release raise concerns about full compliance and transparency. The CPV code is also slightly misaligned with the product.

While the procurement process steps are clearly outlined, the absence of specified evaluation criteria, financial requirements, and detailed technical specifications significantly reduces the overall clarity for potential bidders.

Basic tender information is well-provided, but the critical absence of the full tender documentation (requiring an NDA first), mandatory exclusion grounds, and detailed evaluation/financial criteria makes the tender incomplete.

The requirement for an NDA before accessing tender documents and the complete absence of evaluation criteria are significant barriers to fair competition and transparency. While the value is disclosed and e-procurement is enabled, these omissions are critical.

Electronic submission is supported, and key dates are provided. However, the necessity to register on a portal and sign an NDA before accessing the main tender documents adds an unnecessary practical hurdle for potential bidders.

The tender information is largely consistent with populated key fields and logical dates. Minor omissions like the 'Liable Person' field and N/A codes for procedure type are present but do not impact overall consistency significantly.

The tender does not include any explicit criteria or focus on green procurement, social aspects, or innovation, nor is it EU funded, indicating a neutral stance on sustainability considerations.